Atreca logo
Atreca BCEL
$ 0.15 -11.76%

Quarterly report 2023-Q3
added 11-14-2023

report update icon

Atreca Balance Sheet 2011-2025 | BCEL

Annual Balance Sheet Atreca

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

33.1 M - -60.8 M -158 M -114 M -8.05 M - - - - - -

Long Term Debt

60.3 M - - - - - - - - - - -

Long Term Debt Current

3.54 M - - - - - - - - - - -

Total Non Current Liabilities

- - 12.6 M 816 K 106 K 89.9 M - - - - - -

Total Current Liabilities

16.3 M 16.9 M 17.4 M 7.95 M - - - - - - - -

Total Liabilities

76.6 M 45.1 M 30 M 8.76 M 4.67 M 92.7 M - - - - - -

Retained Earnings

-457 M -360 M -250 M -164 M -96.6 M -58.7 M - - - - - -

Total Assets

155 M 200 M 272 M 196 M 122 M 36.1 M - - - - - -

Cash and Cash Equivalents

30.8 M 94.7 M 60.8 M 158 M 115 M - - - - - - -

Book Value

78.4 M 155 M 242 M 187 M 117 M -56.6 M - - - - - -

Total Shareholders Equity

78.4 M 155 M 242 M 187 M -93 M - - - - - - -

All numbers in USD currency

Quarterly Balance Sheet Atreca

2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

- 58.4 M 59.4 M 60.3 M 61.3 M 62.2 M 63 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

15.6 M 70.4 M 73.5 M 76.6 M 75.8 M 75.6 M 75.9 M 45.1 M 44.8 M 42.2 M 40.4 M 30 M 30 M 30 M 30 M 8.76 M 8.76 M 8.76 M 8.76 M 5.05 M 5.05 M 5.05 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

-533 M -497 M -478 M -457 M -436 M -413 M -385 M -360 M -330 M -303 M -276 M -250 M -250 M -250 M -250 M -164 M -164 M -164 M -164 M -96.6 M -96.6 M -96.6 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Assets

26.3 M 115 M 134 M 155 M 172 M 191 M 214 M 200 M 220 M 241 M 262 M 272 M 272 M 272 M 272 M 196 M 196 M 196 M 196 M 122 M 122 M 122 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

13.5 M 27.7 M 39.5 M 30.8 M 22 M 27.9 M 50 M 94.7 M 115 M 95.1 M 89.7 M 62.4 M 60.8 M 60.8 M 60.8 M 158 M 158 M 158 M 158 M 115 M 115 M 115 M - 8.24 M - - - - - - - - - - - - - - - - - - - - - - - - - - -

Book Value

10.8 M 44.7 M 61 M 78.4 M 96.3 M 115 M 138 M 155 M 175 M 199 M 221 M 242 M 242 M 242 M 242 M 187 M 187 M 187 M 187 M 117 M 117 M 117 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

10.8 M 44.7 M 61 M 78.4 M 96.3 M 115 M 138 M 155 M 175 M 199 M 221 M 242 M 242 M 242 M 242 M 187 M 187 M 187 M 187 M -93 M -93 M -93 M -64.1 M -56.6 M - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Balance Sheet is a fundamental financial report of Atreca, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
Cellectis S.A. Cellectis S.A.
CLLS
$ 4.3 12.57 % $ 116 M franceFrance
Graybug Vision Graybug Vision
GRAY
$ 0.44 -11.23 % $ 9.65 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
$ 11.3 -10.17 % $ 12.2 K -
Galera Therapeutics Galera Therapeutics
GRTX
$ 0.14 -32.59 % $ 7.61 M usaUSA
Cyclerion Therapeutics Cyclerion Therapeutics
CYCN
$ 2.52 -1.18 % $ 6.35 M usaUSA
AnPac Bio-Medical Science Co., Ltd. AnPac Bio-Medical Science Co., Ltd.
ANPC
$ 4.37 -1.58 % $ 28.1 M chinaChina
Caladrius Biosciences Caladrius Biosciences
CLBS
$ 0.43 -16.75 % $ 25.8 M usaUSA
Sorrento Therapeutics Sorrento Therapeutics
SRNE
$ 0.27 -29.58 % $ 126 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
$ 184.71 0.49 % $ 251 B cayman-islandsCayman-islands
Midatech Pharma plc Midatech Pharma plc
MTP
$ 0.29 -18.52 % $ 27.3 M britainBritain
Aeterna Zentaris Aeterna Zentaris
AEZS
$ 5.72 5.93 % $ 314 M canadaCanada
ContraFect Corporation ContraFect Corporation
CFRX
$ 1.47 -5.16 % $ 5.39 M usaUSA
Orchard Therapeutics plc Orchard Therapeutics plc
ORTX
$ 4.93 1.02 % $ 90.8 M britainBritain
Advaxis Advaxis
ADXS
$ 0.31 -9.65 % $ 45.9 M usaUSA
Heat Biologics, Inc. Heat Biologics, Inc.
HTBX
$ 3.93 -5.76 % $ 99.8 M usaUSA
La Jolla Pharmaceutical Company La Jolla Pharmaceutical Company
LJPC
$ 6.2 - $ 154 M usaUSA
Zymeworks Zymeworks
ZYME
$ 6.42 - $ 404 M canadaCanada
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
$ 10.5 - $ 231 M usaUSA
Kadmon Holdings, Inc. Kadmon Holdings, Inc.
KDMN
$ 9.5 - $ 1.7 B usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
$ 2.58 -4.8 % $ 255 M usaUSA
Zosano Pharma Corporation Zosano Pharma Corporation
ZSAN
$ 0.56 7.23 % $ 2.72 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
$ 0.5 - $ 7.46 M israelIsrael
Generation Bio Co. Generation Bio Co.
GBIO
$ 6.33 1.61 % $ 408 M usaUSA
Kiromic BioPharma Kiromic BioPharma
KRBP
$ 3.15 6.61 % $ 3.08 M usaUSA
Acceleron Pharma Inc. Acceleron Pharma Inc.
XLRN
$ 179.68 - $ 10.9 B usaUSA
Albireo Pharma Albireo Pharma
ALBO
$ 44.15 -0.23 % $ 916 M usaUSA
Stealth BioTherapeutics Corp Stealth BioTherapeutics Corp
MITO
$ 0.32 - $ 23.9 M usaUSA
Trillium Therapeutics Inc. Trillium Therapeutics Inc.
TRIL
$ 18.44 - $ 1.94 B canadaCanada
Kaleido Biosciences Kaleido Biosciences
KLDO
$ 0.29 -3.69 % $ 12.4 M usaUSA
Entasis Therapeutics Holdings Entasis Therapeutics Holdings
ETTX
$ 2.19 - $ 105 M usaUSA
Heron Therapeutics Heron Therapeutics
HRTX
$ 1.35 2.27 % $ 206 M usaUSA
ImmuCell Corporation ImmuCell Corporation
ICCC
$ 6.59 2.17 % $ 53.8 M usaUSA
Humanigen Humanigen
HGEN
$ 0.04 -81.12 % $ 4.28 M usaUSA
Aptinyx Aptinyx
APTX
$ 0.06 -39.0 % $ 4.57 M usaUSA
Tyme Technologies Tyme Technologies
TYME
$ 0.31 8.07 % $ 54 M usaUSA
Keros Therapeutics Keros Therapeutics
KROS
$ 15.96 1.98 % $ 598 M usaUSA
Forward Pharma A/S Forward Pharma A/S
FWP
$ 2.64 -0.75 % $ 18.7 M danmarkDanmark
Krystal Biotech Krystal Biotech
KRYS
$ 187.18 2.27 % $ 5.35 B usaUSA
Kymera Therapeutics Kymera Therapeutics
KYMR
$ 56.29 -1.11 % $ 4.22 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
$ 0.39 - $ 26.5 M usaUSA
Celyad Oncology SA Celyad Oncology SA
CYAD
$ 0.47 - $ 12.5 M belgiumBelgium
Brickell Biotech Brickell Biotech
BBI
$ 2.11 -5.38 % $ 6.06 M usaUSA
Genocea Biosciences Genocea Biosciences
GNCA
$ 0.05 -15.0 % $ 3.04 M usaUSA
Codiak BioSciences Codiak BioSciences
CDAK
$ 0.06 -55.98 % $ 2.15 M usaUSA
Concert Pharmaceuticals Concert Pharmaceuticals
CNCE
$ 8.37 - $ 401 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
$ 3.17 1.93 % $ 17.4 M usaUSA
Calithera Biosciences Calithera Biosciences
CALA
$ 0.37 -10.95 % $ 876 K usaUSA
Forma Therapeutics Holdings Forma Therapeutics Holdings
FMTX
$ 20.01 - $ 958 M usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
$ 49.55 -6.81 % $ 3.04 B usaUSA
Sierra Oncology Sierra Oncology
SRRA
$ 54.89 -0.05 % $ 1.34 B canadaCanada